Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Peripheral T-cell lymphoma (PTCL) is a rare group of typically fast-growing Non-Hodgkin's Lymphomas (NHL) that originates from mature T-cells and natural killer (NK) cells, which are mature-stage white blood cells. This subtype of NHL specifically affects T-cells and occurs when these cells develop and proliferate abnormally. Patients diagnosed with PTCL often face a grim prognosis characterized by multiple relapses and resistance to initial treatment. Relapsed or Refractory Peripheral T-cell lymphoma refers to a condition where the disease reappears or grows again after a period of remission (relapsed) or when the lymphoma does not respond to treatment (refractory), meaning that the cancer cells continue to grow, or when the response to treatment does not last very long. Median overall survival for relapsed patients had a longer survival period at 29.1 months compared to refractory patients with only 12.3 months. One-year survival rates are influenced by the response to the initial therapy, with 84% survival among relapsed patients and 52% among refractory patients. Among all relapsed and refractory patients, those achieving a complete response to second-line therapy had a notably extended survival compared to those with a partial response or worse. Recently, the FDA approved four next-generation drugs (pralatrexate, romidepsin, brentuximab vedotin, and belinostat) for treating relapsed and refractory PTCL based on their response rates. However, none of these agents led to improvements in overall survival. The European Medicines Agency (EMA) declined to approve both pralatrexate and romidepsin due to a lack of clear clinical benefits, and belinostat is not licensed in Europe despite being granted orphan designation status by the EMA. Brentuximab vedotin is the only drug approved by the EMA to treat relapsed or refractory systemic ALCL, primarily due to a more favorable benefits-to-risks ratio.

 

Thelansis’s “Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL), Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) market outlook, Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) competitive landscape, Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypoglycemia and severe
Read more